Close
Get it on Google Play

Y-mAbs Therapeutics (YMAB) receives FDA CRL for omburtamab

December 1, 2022 5:37 PM EST Send to a Friend
Y-mAbs Therapeutics, Inc. (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login